FDA approves Medtronic's Marquis ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
The US FDA has approved for sale the first product in Medtronic's new generation of implantable cardioverter defibrillators (ICDs). The Marquis DR dual-chamber ICD offers a charge time of just 7.5 seconds - ie the time needed before the device delivers a life-saving therapy after an abnormal heart rhythm is detected. The 36cc product also incorporates a battery that can last 7-8 years, resulting in less frequent device replacement for the patient. The device is being launched in the US, Canada and Europe, says the firm.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.